Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.0K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.0K
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

695
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
695
Pharmacodynamics: Overview and Principles01:21

Pharmacodynamics: Overview and Principles

3.8K
Pharmacodynamics is a scientific field that delves into drugs' intricate biochemical, cellular, and physiological effects on the human body. The study of pharmacodynamics helps us understand how drugs interact with the body and elicit various responses.
Most drugs' effects result from their interactions with drug receptors or targets within the body. These interactions trigger specific responses at the cellular or systemic level. Drug receptors can be found on the surfaces of cells or...
3.8K
Pharmacokinetics: Overview01:10

Pharmacokinetics: Overview

10.6K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
10.6K
Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

2.0K
Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable PVI and AF Recurrence: Disconnecting the Dots.

JACC. Clinical electrophysiology·2026
Same author

Considerations for Using Atrial Fibrillation Burden as a Surrogate Endpoint A Report from the Cardiovascular Sciences Research Consortium.

American heart journal·2026
Same author

Experiences of Patients With Atrial Fibrillation Using Technology to Personalize Self-Care Decision-Making: Interpretive Description Study.

JMIR cardio·2026
Same author

Tetralogy of Fallot: electrophysiology-guided surgical ablation during pulmonary valve replacement.

European heart journal·2026
Same author

Clinical Diagnosis of Calcium Release Deficiency Syndrome in a Family With Sudden Cardiac Death.

JAMA cardiology·2026
Same author

CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne·2026
Same journal

Sweating the Details: A Reflective Pause in our Procedural Workflow.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale and Atrial Septal Defect.

Cardiac electrophysiology clinics·2026
Same journal

Patent Foramen Ovale Embryology, Anatomy, and Physiology.

Cardiac electrophysiology clinics·2026
Same journal

Management of Arrhythmias in the Cardiovascular Intensive Care Unit.

Cardiac electrophysiology clinics·2026
Same journal

Left Ventricular Assist Device Emergencies: Diagnosis and Management.

Cardiac electrophysiology clinics·2026
Same journal

Advanced Critical Care Techniques in the Field.

Cardiac electrophysiology clinics·2026
See all related articles

Related Experiment Video

Updated: Mar 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Dronedarone: Basic Pharmacology and Clinical Use.

Rafik Tadros1, Stanley Nattel1, Jason G Andrade2

  • 1Department of Medicine, Université de Montréal and Montreal Heart Institute, 5000 Rue Belanger, Montreal, Québec H1T 1C8, Canada.

Cardiac Electrophysiology Clinics
|June 5, 2016
PubMed
Summary
This summary is machine-generated.

Dronedarone helps maintain sinus rhythm in nonpermanent atrial fibrillation (AF) patients, reducing AF recurrence and hospitalizations. However, it should be avoided in permanent AF and severe heart failure due to increased mortality risks.

Keywords:
Antiarrhythmic drugAtrial fibrillationDronedaroneRhythm control

More Related Videos

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
09:18

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study

Published on: March 31, 2022

3.1K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Related Experiment Videos

Last Updated: Mar 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K
Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study
09:18

Intraventricular Drug Delivery and Sampling for Pharmacokinetics and Pharmacodynamics Study

Published on: March 31, 2022

3.1K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) is a common arrhythmia.
  • Maintaining sinus rhythm is crucial for AF management.
  • New antiarrhythmic drugs are needed to improve patient outcomes.

Purpose of the Study:

  • To evaluate the efficacy and safety of dronedarone.
  • To assess dronedarone's role in managing nonpermanent atrial fibrillation.

Main Methods:

  • Dronedarone is a multi-channel blocker.
  • Electrophysiologic properties were assessed.
  • Clinical outcomes in AF patients were analyzed.

Main Results:

  • Dronedarone decreases AF recurrence and ventricular rate.
  • It reduces cardiovascular hospitalizations in paroxysmal and persistent AF.
  • Dronedarone increases mortality in permanent AF and moderate-severe heart failure patients.

Conclusions:

  • Dronedarone is indicated for maintaining sinus rhythm in specific AF populations.
  • It offers a less toxic alternative to amiodarone but with lower efficacy.
  • Contraindicated in permanent AF and moderate-severe heart failure.